Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
Outset Medical, Inc. (OM) reports that its General Counsel, John Brottem, has decided to depart from the company and his role, effective September 11, 2026, to pursue other professional opportunities. The company states that his departure is not due to any dispute or disagreement with the company or its management.
Outset Medical, Inc. (OM) reported that Chair and CEO Leslie Trigg sold 3,437 shares of Common Stock on August 17, 2026 at $4.39 per share. According to the disclosure, this was a mandatory “sell to cover” transaction to satisfy tax withholding obligations on the vesting of 9,319 RSU-based shares, and is described as not a discretionary trade. Following the sale, Trigg held 194,597 shares directly, plus indirect holdings of 41,666 shares through the Trigg 2002 Rev Trust and 584 shares through the Trigg Family Trust.
Outset Medical, Inc. (OM) reported that General Counsel John L. Brottem sold 2,632 shares of common stock on 2026-08-17 at $4.39 per share. According to the company’s disclosure, the shares were sold in a non-discretionary “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting of 5,033 RSU-based shares granted in 2024 and 2025. After this transaction, Brottem directly holds 87,475 shares of Outset Medical common stock.
Outset Medical, Inc. (OM) reported that its Chief Financial Officer, Renee Gaeta, sold 4,543 shares of common stock on August 17, 2026 at $4.39 per share. After this transaction, Gaeta directly holds 180,840 shares. According to the company’s disclosure, the shares were sold in a “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting of 12,322 RSU-based shares granted on June 10, 2025 and do not represent a discretionary trade.
Outset Medical (OM) reporting person Leslie Trigg filed a notice of proposed stock sales. The filing lists up to 3,344 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on or after August 17, 2026 on NASDAQ, with an estimated aggregate market value of $15,079.88. These shares are tied to the settlement of 9,319 vested restricted stock units on August 15, 2026 as equity compensation for services rendered. The filing also reports that 3,445 shares of common stock were sold on May 15, 2026 for $12,746.50 in the prior three months.
Outset Medical (OM) has a notice of proposed sale of common stock by reporting person John Brottem. The filing lists 2,562 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on August 17, 2026, with an aggregate market value of $11,549.17. It also notes the settlement of 5,033 vested restricted stock units as equity compensation for services rendered, with the same August 17, 2026 date. In the prior three months, the reporting person sold 2,638 shares of common stock on May 15, 2026 for $9,760.60.
OM insider Renee Gaeta filed a notice for the potential sale of 4,422 shares of common stock through Morgan Stanley Smith Barney LLC on or after August 17, 2026 on NASDAQ, with an indicated value of $19,939.32. The shares relate to 12,322 shares acquired from the settlement of vested restricted stock units dated August 15, 2026. Over the prior three months, Gaeta reported sales of 17,672 shares of OM common stock for $87,384.92.
Bank of America Corporation reported beneficial ownership of 666,596 shares of Outset Medical, Inc. common stock, representing 3.5% of the class based on 18,797,000 shares outstanding as of June 30, 2026. All voting and dispositive authority is reported as shared, with no sole power to vote or dispose of any shares.
The filing attributes shared voting power over 666,542 shares and shared dispositive power over 666,587 shares. The position is held through Bank of America Corporation and its wholly owned subsidiaries BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, and Merrill Lynch Pierce Fenner & Smith, Inc., and is characterized as ownership of 5 percent or less of the class.
AQR Capital Management Holdings, LLC and its wholly owned subsidiary AQR Capital Management, LLC report beneficial ownership of Outset Medical, Inc. common stock. They beneficially own 998,961 shares of common stock, representing 5.39% of the outstanding class.
The AQR entities report shared voting power over 966,795 shares and shared dispositive power over 998,961 shares, with no sole voting or dispositive power over any shares. Both entities are organized in the United States and are reporting as parent holding company and subsidiary.